BG Medicine, which develops and commercializes molecular diagnostics based on biomarkers, announced terms for its IPO on Tuesday. The Waltham, MA-based company plans to raise $67 million by offering 4.75 million shares at a price range of $13-$15. At the mid-point of the proposed range, BG Medicine will command a market value of $290 million. BG Medicine, which was founded in 2000 and booked $1 million in sales for the 12 months ended June 30, plans to list on the NASDAQ under the symbol BGMD. UBS Investment Bank is the lead underwriter on the deal, for which timing was not disclosed.
